<DOC>
	<DOCNO>NCT02847403</DOCNO>
	<brief_summary>The overall objective study assess potential effect long-acting GLP-1 analogue exenatide preventing/slowing progression cognitive dysfunction relate biomarkers dysglycemic/prediabetic patient mild cognitive impairment ( MCI ) .</brief_summary>
	<brief_title>Long-acting Exenatide Cognitive Decline Dysglycemic Patients</brief_title>
	<detailed_description>Type 2 Diabetes Mellitus ( T2DM ) Alzheimer 's Disease ( AD ) two common disease aging.The presence T2DM almost double risk develop AD associate faster rate cognitive decline mild cognitive impairment ( MCI ) . Blood glucose level directly associate accelerate cognitive decline also subject impaired fast glucose individual without clinical DM . Impaired insulin signal critically involved natural history T2DM AD may represent common mechanistic link ( `` common soil '' ) dysglycemic/prediabetic state AD development progression . The overall objective study assess potential effect long-acting GLP-1 analogue exenatide preventing/slowing progression cognitive dysfunction relate biomarkers dysglycemic/prediabetic patient mild cognitive impairment ( MCI ) . All eligible patient V0 undergo baseline assessment ( V1 ) allocate accord procedure randomization one study arm . Follow-up ( FU ) visit subject 16 ( V2 ) 32 week ( V3 ) randomization . Additionally , subject active treatment admit weekly Outpatient Diabetes Unit AOUPR GLP-1 subcutaneous injection check possible side effect . Subjects control arm see Center Dementia ( AOUPR ) accord usual schedule . Laboratory diagnostic : At study visit patient undergo : - anthropometric hemodynamic assessment : weight height Body Mass Index ( BMI ) calculation , waist circumference , ambulatory blood pressure , heart rate ; - blood test collection metabolic profile : blood collection metabolic/hormonal profile : fasting plasma glucose , HbA1c , insulin , C-peptide , glucagon , active GLP-1 , total gastric inhibitory polypeptide ( GIP ) , total cholesterol , HDL-cholesterol , triglyceride , AST , ALT , pancreatic amylase , lipase , creatinine , eGFR . - cognitive function test : ADAS-cog quality score MMSE , Phonemic verbal fluency test ; Semantic verbal fluency test ; Geriatric Depression Scale ( GDS ) ; Clinical Dementia Rating Scale ( CDR ) ; Neuropsychiatric Inventory ( NPI ) ; Activities Daily Living ( ADL ) ; Instrumental Activities Daily Living ( IADL ) . ADAS-cog designed measure severity important symptom Alzheimer 's disease . It consist 11 7 task measure disturbance memory , language , praxis , attention cognitive ability often refer core symptom AD . - Functional Magnetic Resonance Imaging ( MRI ) ( V1 V3 ) .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>patient capable give informed consent dysglycemia/prediabetes define fast plasma glucose 100 125 mg/dl and/or 2hour plasma glucose 140 199 mg/dl 75 g OGTT and/or HbA1c value 5.7 6.4 % diagnosis MCI accord Petersen clinical criterion ( expect correct score MMSE 24 27 ) age &gt; 50 &lt; 80 yr stable medication past 3 month Caucasian ethnicity age &lt; 50 &gt; 80 yrs incapability give inform consent diabetes define accord American Diabetes Association ( ADA ) criteria clinically significant liver kidney dysfunction define sALT &gt; 2 time upper reference estimate creatinineclearance ( eGFR ) &lt; 60 mL / min/1.73m2 , assess CKDEPI formula endocrinological disease well control hypothyroidism , personal family history medullary thyroid carcinoma Multiple Endocrine Neoplasia ( MEN ) syndrome , severe gastrointestinal disease ( i.e gastroparesis , dump syndrome ) , current history chronic acute pancreatitis contraindication use exenatide per Summary Product Characteristics known abuse alcohol drug ferromagnetic prosthesis , pacemaker metal incorporate body significant neurologic disease MCI ( i.e . Parkinson 's disease , multiple system atrophy , normal pressure hydrocephalus , progressive supranuclear palsy , subarachnoid hemorrhage , brain neoplasm , Huntington disease , epilepsy head trauma ) BMI ≤22 Kg/m2 subject ≥ 70 yr MRI/CT show unambiguous etiological evidence cerebrovascular disease regard MCI severe sensory defect ; current presence clinically significant psychiatric disorder warfarin treatment , clinically significant systemic condition history cancer within last 5 yr know allergy exenatide component .</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>dysglycemia</keyword>
	<keyword>MCI</keyword>
	<keyword>exenatide LAR</keyword>
	<keyword>GLP-1</keyword>
</DOC>